Candel Therapeutics (CADL) Competitors $7.91 -1.07 (-11.92%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$7.98 +0.07 (+0.83%) As of 03/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CADL vs. KNSA, DYN, SNDX, VIR, NRIX, PRAX, ADPT, DAWN, ARDX, and GPCRShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Syndax Pharmaceuticals (SNDX), Vir Biotechnology (VIR), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Adaptive Biotechnologies (ADPT), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Kiniksa Pharmaceuticals Dyne Therapeutics Syndax Pharmaceuticals Vir Biotechnology Nurix Therapeutics Praxis Precision Medicines Adaptive Biotechnologies Day One Biopharmaceuticals Ardelyx Structure Therapeutics Candel Therapeutics (NASDAQ:CADL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership. Is CADL or KNSA more profitable? Candel Therapeutics has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Which has better earnings and valuation, CADL or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,140.71-$37.94M-$1.73-4.57Kiniksa Pharmaceuticals$423.24M3.66$14.08M-$0.61-35.18 Which has more volatility & risk, CADL or KNSA? Candel Therapeutics has a beta of -1.25, suggesting that its share price is 225% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Does the MarketBeat Community prefer CADL or KNSA? Kiniksa Pharmaceuticals received 157 more outperform votes than Candel Therapeutics when rated by MarketBeat users. However, 65.22% of users gave Candel Therapeutics an outperform vote while only 65.15% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes1565.22% Underperform Votes834.78% Kiniksa PharmaceuticalsOutperform Votes17265.15% Underperform Votes9234.85% Do analysts prefer CADL or KNSA? Candel Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 165.49%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, indicating a potential upside of 70.55%. Given Candel Therapeutics' higher possible upside, research analysts plainly believe Candel Therapeutics is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CADL or KNSA? In the previous week, Kiniksa Pharmaceuticals had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 26 mentions for Kiniksa Pharmaceuticals and 20 mentions for Candel Therapeutics. Kiniksa Pharmaceuticals' average media sentiment score of 0.27 beat Candel Therapeutics' score of 0.15 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders believe in CADL or KNSA? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryKiniksa Pharmaceuticals beats Candel Therapeutics on 12 of the 17 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$256.89M$3.08B$5.81B$8.40BDividend YieldN/A1.51%4.75%3.98%P/E Ratio-4.5728.6624.9519.25Price / Sales2,140.71403.87375.55110.22Price / CashN/A168.6838.0534.58Price / Book17.983.487.334.28Net Income-$37.94M-$71.55M$3.18B$247.04M7 Day Performance-5.72%-5.00%-2.87%-3.25%1 Month Performance1.28%-10.68%-6.77%-6.55%1 Year Performance379.39%-22.37%12.32%4.01% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.9947 of 5 stars$7.91-11.9%$21.00+165.5%+365.3%$256.89M$120,000.00-4.5760Short Interest ↑KNSAKiniksa Pharmaceuticals2.4049 of 5 stars$19.63-1.9%$36.60+86.4%-1.3%$1.42B$270.26M-140.20220Earnings ReportShort Interest ↑DYNDyne Therapeutics3.192 of 5 stars$13.59-3.0%$49.91+267.2%-57.7%$1.38BN/A-3.82100Earnings ReportAnalyst ForecastAnalyst RevisionSNDXSyndax Pharmaceuticals3.6184 of 5 stars$15.67-4.3%$36.20+131.0%-34.7%$1.34B$16M-4.32110Earnings ReportNews CoverageGap UpVIRVir Biotechnology3.7777 of 5 stars$9.47-1.0%$34.83+267.8%-29.5%$1.30B$86.18M-2.42580Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownNRIXNurix Therapeutics2.0084 of 5 stars$16.86-0.1%$31.81+88.7%+4.6%$1.28B$54.55M-5.83300News CoveragePositive NewsPRAXPraxis Precision Medicines2.309 of 5 stars$66.71-10.4%$145.20+117.7%-32.3%$1.24B$2.45M-6.48110Earnings ReportAnalyst ForecastNews CoverageADPTAdaptive Biotechnologies3.5748 of 5 stars$8.42+1.8%$9.10+8.1%+101.0%$1.24B$178.96M-7.72790Positive NewsDAWNDay One Biopharmaceuticals2.5667 of 5 stars$12.18-2.0%$35.71+193.2%-52.7%$1.23BN/A-11.8360Earnings ReportAnalyst RevisionARDXArdelyx4.5864 of 5 stars$5.13+1.4%$9.93+93.5%-45.6%$1.22B$251.85M-32.0690GPCRStructure Therapeutics2.7457 of 5 stars$21.03-11.5%$81.29+286.5%-45.8%$1.20BN/A-28.42136Earnings Report Related Companies and Tools Related Companies KNSA Competitors DYN Competitors SNDX Competitors VIR Competitors NRIX Competitors PRAX Competitors ADPT Competitors DAWN Competitors ARDX Competitors GPCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CADL) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CADL Stock Alerts